ResMed, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7611521078
USD
251.51
0.07 (0.03%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ResMed, Inc. stock-summary
stock-summary
ResMed, Inc.
Pharmaceuticals & Biotechnology
ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.
Company Coordinates stock-summary
Company Details
9001 Spectrum Center Blvd , SAN DIEGO CA : 92123-1438
stock-summary
Tel: 1 858 7462400
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 154 Schemes (30.51%)

Foreign Institutions

Held by 395 Foreign Institutions (19.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Peter Farrell
Non-Executive Chairman of the Board
Mr. Michael Farrell
Chief Executive Officer, Director
Mr. Ronald Taylor
Lead Independent Director
Ms. Carol Burt
Independent Director
Mr. Jan De Witte
Independent Director
Ms. Karen Drexler
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,348 Million
(Quarterly Results - Jun 2025)
Net Profit:
380 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 52,609 Million (Mid Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.45%

stock-summary
Debt Equity

-0.09

stock-summary
Return on Equity

23.36%

stock-summary
Price to Book

8.82